Dry Eye Treatment Options: A Complete Overview
There is no single treatment for dry eye disease, because there is no single cause. Modern practice, as set out in TFOS DEWS III, characterises the specific drivers a patient carries and matches each to a treatment with a genuine evidence base (TFOS DEWS III, 2025, American Journal of Ophthalmology). This overview lays out the options and shows where light-based therapy sits.
Artificial tears and lubricants
Drops are the most common first step. They supplement or stabilise the tear film and can ease symptoms, and ingredients such as hyaluronic acid have an evidence base for the tear-film component. Their limitation is that they manage symptoms rather than treating the underlying drivers, the relief is temporary, and adherence over the long term is a real burden.
Warm compresses and lid hygiene
For the very common meibomian gland dysfunction and blepharitis, warmth and lid hygiene aim to soften and express the glands' oil and reduce lid-margin inflammation. They help, but they demand sustained daily effort and many patients struggle to maintain them, so the benefit often fades.
Meibomian gland expression and procedures
In-office expression of the glands can clear blockages, but it can be uncomfortable, needs repeating, and addresses the symptom of blockage rather than the inflammatory drivers behind it.
Intense pulsed light (IPL)
IPL targets the inflammatory and vascular component at the lid, and is well established for the lid-driven disease seen in ocular rosacea and recalcitrant MGD. Traditional IPL generally requires coupling gel, eye protection and attention to skin type.
Low-level light therapy (photobiomodulation)
LM™ LLLT (PBM) is distinctive because it acts across all three DEWS III driver groups, the tear film, the eyelids and the ocular surface, through a cellular mechanism rather than warmth or expression. Because most patients carry several drivers at once, a modality that addresses several is unusually practical, and its favourable tolerability lets it be offered to almost anyone. It serves as the primary modality, with IPL added as an adjunct for severe, lid-driven cases. See the comparisons of light therapy versus drops and compresses and in-office versus home care.
Choosing among them
The right plan is individual and set by the eye care professional after a proper workup. The trend the evidence supports is toward treating the drivers directly, and light-based therapy on eye-light® is one of the few options that spans them.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.